Title:A Retrospective Analysis of the Lauren Classification in the Choice of
XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
Volume: 24
Issue: 2
Author(s): Ke Wang, Yuanyuan Yu, Jian Zhao, Qianhao Meng, Chang Xu, Jing Ren, Yanqiao Zhang, Yusheng Wang*Guangyu Wang*
Affiliation:
- Department of Digestive, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated
to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,
Taiyuan, China
- Department of Gastrointestinal Medical Oncology, The Third Affiliated Hospital of Harbin Medical University Cancer
Hospital, Harbin, China
Keywords:
Lauren subtype, adjuvant chemotherapy, gastric cancer, capecitabine plus oxaliplatin, S- 1 plus oxaliplatin, survival.
Abstract:
Background: We aim to retrospectively explore the guiding value of the Lauren classification
for patients who have undergone D2 gastrectomy to choose oxaliplatin plus capecitabine
(XELOX) or oxaliplatin plus S-1 (SOX) as a further systemic treatment after the operation.
Methods: We collected data of 406 patients with stage III gastric cancer(GC)after radical D2 resection
and regularly received XELOX or SOX adjuvant treatment after surgery and followed
them for at least five years. According to the Lauren classification, we separated patients out into
intestinal type (IT) GC together with non-intestinal type(NIT) GC. According to the chemotherapy
regimen, we separated patients into the SOX group together with the XELOX group.
Results: Among non-intestinal type patients, the 3-year DFS rates in the SOX group and the
XELOX group were 72.5%, respectively; 54.5% (P=0.037); The 5-year OS rates were 66.8% and
51.8% respectively (P=0.038), both of which were statistically significant.
Conclusion: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences
were counted without being statistically significant with intestinal-type GC in the SOX or
XELOX groups.
